X4 Pharmaceuticals (XFOR) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Focused on developing and commercializing therapeutics for rare hematology diseases, with XOLREMDI (mavorixafor) as the lead product approved in the US and EU for WHIM syndrome, with commercialization in the EU led by Norgine.
Progressing the pivotal Phase 3 4WARD trial for chronic neutropenia, with over 110 active sites, strengthened clinical operations via a top CRO, and ongoing FDA discussions.
Completed transfer of EU marketing authorization for XOLREMDI to Norgine following regulatory approval.
Cash runway projected into 2029, supporting ongoing clinical and commercial activities.
Financial highlights
Total revenue for Q2 2026 was $8.8M, with $2.4M from US product sales and $6.4M from the Norgine license agreement.
Net product sales grew to $2.4M in Q2 2026 from $1.7M in Q2 2025, driven by increased patient prescriptions.
Net loss for Q2 2026 was $16.2M ($0.13 per share), improved from $25.7M ($3.47 per share) in Q2 2025.
R&D expenses for Q2 2026 were $15.1M, down from $18.4M year-over-year, mainly due to reduced headcount post-2025 restructuring.
Cash, cash equivalents, and marketable securities totaled $208.0M as of June 30, 2026; another report lists $195.1M.
Outlook and guidance
Current cash and equivalents expected to fund operations and debt obligations for at least the next 12 months, with some projections extending the runway into 2029.
Additional capital will be needed to fund operations beyond this period; future funding may come from equity, debt, or partnerships.
Update on FDA meeting and 4WARD trial enrollment completion expected by end of Q3 2026.
Potential to receive up to €221M in milestone payments and escalating double-digit royalties from Norgine for EU commercialization.
Ongoing focus on completing the 4WARD trial and expanding XOLREMDI's market presence.
Latest events from X4 Pharmaceuticals
- 4WARD data expected in early 2028; 4STEPS will test G-CSF dose reduction.XFOR
Jefferies Global Healthcare Conference - 4WARD enrollment targets year-end 2026, with topline data expected in Q1 2028.XFOR
Stifel 2026 Healthcare Conference 2026 - 4WARD enrollment is targeted for year-end 2026; top-line results are expected in Q1 2028.XFOR
3rd Annual Guggenheim Healthcare Innovation Conference - Higher product sales and 4WARD progress accompany debt refinancing and runway into Q1 2029.XFOR
Q3 2026 - Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFOR
Corporate presentation - Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029.XFOR
Wells Fargo 21st Annual Healthcare Conference - Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFOR
Q2 2024 - Mavorixafor durably increased ANC and showed good tolerability in chronic neutropenia Phase 2.XFOR
Study Update